Screening and treatment would save disability in young people during their most productive years.
Across New Zealand, three pediatric eye conditions — chronic eyelid inflammation, a cornea-thinning disease that strikes teenagers, and a retinal disorder threatening premature infants — are drawing renewed clinical attention as evidence mounts that early intervention can preserve sight and reshape life trajectories. The burden falls unevenly: Māori and Pacific youth face disproportionate risk from keratoconus and retinopathy of prematurity, making this not merely a medical challenge but a question of equity and intergenerational opportunity. New Zealand's health system now holds the tools — from corneal crosslinking to anti-VEGF therapies to AI-assisted imaging — and the evidence to act; what remains is the will to move swiftly enough to reach the children most at risk.
- Three pediatric eye diseases are quietly eroding vision and opportunity for New Zealand children, with damage often entrenched before families or clinicians recognize the warning signs.
- Māori and Pacific youth bear a sharply disproportionate share of the burden — Pasifika patients received 43 percent of keratoconus-related corneal transplants despite representing just 7 percent of the population.
- A 2025 economic analysis found that screening all 15-year-olds for keratoconus and treating with corneal crosslinking would save over $1,200 per quality-adjusted life year — making inaction the more expensive choice.
- Anti-VEGF therapies have overtaken laser as the preferred treatment for retinopathy of prematurity, delivering better structural outcomes, though they require ongoing vigilance for avascular retinal zones that may reactivate years later.
- New Zealand has deployed super widefield retinal cameras nationally and is piloting AI-assisted screening systems, signalling a system beginning to move — but the pace of implementation will determine how many children are reached in time.
New Zealand's eye health system is grappling with three pediatric conditions that, without timely intervention, can permanently alter the sight — and futures — of children and their families.
The first, pediatric blepharokeratoconjunctivitis, is a chronic inflammation of the eyelid margins and corneal surface that often masquerades as minor irritation until corneal scarring and abnormal blood vessel growth have already taken hold. Children suffer photophobia and discomfort that can quietly undermine schooling and daily life. Treatment is effective when applied consistently: warm compresses, lubricating drops, topical anti-inflammatories, and oral azithromycin — which persists longer in ocular tissue than older alternatives — form a reliable toolkit. The condition is unglamorous but manageable if caught early.
Keratoconus carries a different urgency. This progressive thinning and outward coning of the cornea strikes teenagers and young adults at the very moment vision matters most for education and opportunity. A Markov modelling study published in late 2025 found that screening all 15-year-olds and treating positive cases with corneal crosslinking — which stiffens the cornea and halts progression — would save approximately $1,278 per quality-adjusted life year compared to standard care, outperforming even routine cataract surgery on cost-effectiveness grounds. Yet the disease falls hardest on those least positioned to absorb its consequences: up to 2.2 percent of Māori high school students are affected, and Pasifika patients account for 43 percent of keratoconus-related corneal transplants despite representing only 7 percent of the population. An action plan exists; the evidence now demands its rapid execution.
Retinopathy of prematurity rounds out the triad. Premature infants face abnormal retinal blood vessel growth that can lead to detachment and blindness — a condition responsible for 18 percent of childhood blindness in New Zealand. Anti-VEGF therapies have largely supplanted laser treatment, producing better structural outcomes and lower rates of severe myopia, though they can leave avascular retinal zones requiring long-term monitoring. ROP survivors carry elevated lifetime risks of glaucoma and ocular hypertension. In response, New Zealand rolled out super widefield retinal cameras nationally in 2025 and introduced a digital image-sharing platform to standardise screening. AI-assisted detection systems are now being piloted in major centres, promising earlier identification and more reliable care coordination.
What unites these three conditions is a shared logic: all are more treatable when caught early, all fall disproportionately on vulnerable communities, and all have interventions that New Zealand is now equipped to deploy. The clinical case is settled. The remaining question is one of speed — and of whether the system will move quickly enough to reach the rangatahi who cannot afford to wait.
New Zealand's eye health system is confronting three pediatric conditions that, left unchecked, can steal sight from children and reshape the lives of their families. A cluster of recent clinical reviews published in 2025 and 2026 maps the current state of care—and reveals where intervention could make the largest difference.
The first condition is pediatric blepharokeratoconjunctivitis, a chronic inflammation of the eyelid margins and corneal surface that often goes unrecognized until damage has already begun. Children experience photophobia, redness, and discomfort—symptoms that can seem minor to parents until the child starts avoiding daylight and struggling in school. Without proper treatment, the cornea scars and new blood vessels grow across it, causing permanent vision loss. The good news is straightforward: warm compresses applied daily remain the foundation of care. Lubricating eye drops help. Topical anti-inflammatory and antimicrobial medications work. Oral azithromycin, a macrolide antibiotic, has emerged as particularly useful because it stays in the body longer and reaches higher concentrations in eye tissue than older alternatives like erythromycin. The condition is not glamorous, and it does not make headlines, but it is treatable if caught early and managed consistently.
Keratoconus presents a different kind of urgency. This progressive corneal disease, which causes the cornea to thin and cone outward, strikes teenagers and young adults—precisely when vision matters most for education and opportunity. A Markov analysis published in late 2025 modeled what would happen if New Zealand screened all 15-year-olds and treated positive cases with corneal crosslinking, a procedure that stiffens the cornea and halts progression. The result: screening plus treatment would save approximately $1,278 per quality-adjusted life year gained compared to standard care—making it cost-effective by any reasonable health system standard. For context, routine cataract surgery costs about $4,380 per quality-adjusted life year and primarily affects retirees. Keratoconus, by contrast, can disable young people for decades.
But there is a stark equity problem embedded in these numbers. Māori and Pacific Islander youth are disproportionately affected by keratoconus. Up to 2.2 percent of Māori high school students have the disease. In the Auckland keratoconus study, 43 percent of corneal transplants performed for keratoconus went to Pasifika patients, despite Pasifika people representing only 7 percent of New Zealand's population. This means that without screening and accessible crosslinking, an entire generation of rangatahi—young people—from these communities faces a higher risk of vision loss and the cascading consequences: limited career options, educational disruption, reduced independence. The Eye Health National Clinical Network has developed a keratoconus action plan. The clinical evidence now supports its rapid implementation.
Retinopathy of prematurity, or ROP, is the third condition commanding attention. Premature infants are at risk of abnormal blood vessel growth in the retina, which can lead to retinal detachment and blindness. For decades, laser therapy was the standard treatment. Then came anti-VEGF drugs—medications that block a growth factor driving the abnormal vessels. These agents produce better structural outcomes and cause less retinal damage than laser. They also result in lower rates of high myopia, the severe nearsightedness that often followed laser treatment. The trade-off is real: anti-VEGF therapy can leave patches of avascular retina—areas without blood vessels—that may reactivate later in childhood or adulthood, requiring additional treatment. Laser still has a role, particularly in managing these peripheral avascular zones.
The long-term picture for ROP survivors is sobering. Adults with a history of ROP face lifelong elevated risk of glaucoma and ocular hypertension. In one untreated ROP series, retinal detachment occurred in 38.6 percent of eyes. In New Zealand, ROP accounts for 18 percent of childhood blindness—a substantial burden for a preventable or treatable condition. The good news is that technology is moving fast. In 2025, New Zealand rolled out super widefield retinal cameras nationally and implemented Harmony, a digital image-sharing platform, to standardize screening and follow-up care across the country. Artificial intelligence systems are being tested in major centers to assist in detecting disease and reducing the workload on clinicians. These tools promise to catch ROP earlier and coordinate care more reliably.
What ties these three conditions together is not their biology but their trajectory: all three are more treatable when caught early, all three disproportionately affect vulnerable populations, and all three have solutions that New Zealand's health system is now positioned to implement. The question is not whether these interventions work. The question is how quickly they will reach the children who need them most.
Citações Notáveis
Keratoconus can cause significant structural changes to the cornea for which surgical treatment options are limited, and Māori and Pacific Peoples are disproportionately affected by this disease.— Clinical commentary on keratoconus screening study
ROP represents 18% of childhood blindness in New Zealand, so we have room to improve.— Clinical commentary on retinopathy of prematurity review
A Conversa do Hearth Outra perspectiva sobre a história
Why does keratoconus screening at age 15 matter so much if the disease is rare?
It's not rare in New Zealand, especially among Māori and Pacific youth. Up to 2.2 percent of Māori high school students have it. That's not a rounding error—that's a public health signal. And once it starts, it progresses fast. By the time a teenager realizes something is wrong with their vision, the cornea may already be significantly damaged.
But the cost-effectiveness analysis—does that really change how the system works?
It should. The analysis shows screening and crosslinking saves money compared to standard care. But more importantly, it prevents disability in young people during their most productive years. Cataract surgery is considered cost-effective at $4,380 per quality-adjusted life year, and that mostly helps retirees. Keratoconus screening costs less and helps teenagers. The math is clear.
What about the equity angle? Why are Pasifika patients overrepresented in corneal transplants?
Because they're not getting screened and treated early. If 43 percent of transplants go to Pasifika patients but they're only 7 percent of the population, that means they're reaching advanced disease at much higher rates. Transplants are a last resort. Screening and crosslinking would prevent most of those transplants from ever being necessary.
And retinopathy of prematurity—is anti-VEGF therapy a complete solution?
No. It's better than laser in many ways, but it leaves peripheral avascular retina—areas without blood vessels. Those can reactivate later. And ROP survivors face lifelong risks of glaucoma and retinal detachment. It's not a cure; it's damage control. But it's much better damage control than we had before.
What's the role of AI in all this?
Screening ROP requires trained specialists to look at retinal images regularly. AI can help identify disease faster and reduce the burden on clinicians. New Zealand just rolled out the technology nationally in 2025. If it works as hoped, more babies at risk will get caught earlier, and care will be more consistent across the country.
So what's the real barrier to implementation?
Not evidence. The evidence is solid. It's resources, training, and making sure the system reaches the communities that need it most. That's the harder part.